Emyria (EMD) Stock Overview

Emyria Limited, a clinical-stage biotech company, engages in the development of treatments for unmet medical needs. The company develops psychedelic-assisted therapy, as well as MDMA drug discovery program. Its drug development program includes EMD-RX5 for treatment of psychological distress and mild stress and anxiety. The company was formerly known as Emerald Clinics Limited and changed its name to Emyria Limited in September 2020. Emyria Limited was founded in 2018 and is headquartered in Leederville, Australia.

EMD Stock Information

Symbol

EMD

Address

D2, 661 Newcastle StreetLeederville, WA 6007Australia

Founded

Trading hours

10:00 AM - 4:00 PM AEST

Website

https://emyria.com

Country

🇦🇺 Australia

Phone Number

61 8 6559 2800

Emyria (EMD) Price Chart

Emyria Overview: Key Details and Summary

Stock data	2023	Change
Price	$0.022433261048381066	N/A
Market Cap	$6.49M	N/A
Shares Outstanding	289.39M	7.73%
Employees	0	N/A
Shareholder Equity	6.79M	7.46%

Valuation	2023	Change
P/E Ratio	-1.26	N/A
P/S Ratio	6.54	N/A
P/B Ratio	0.96	N/A

Growth	2023	Change
Return on Equity	-0.4707	N/A

Earnings	2023	Change
Revenue	$992.34K	N/A
Earnings	-$3.20M	N/A
EPS	-0.0178	N/A
Earnings Yield	-0.792	N/A
Gross Margin	-0.4066	N/A
Operating Margin	-4.47	N/A
Net income margin	-3.22	N/A

Financial Strength	2023	Change
Total Assets	$6.33M	N/A
Total Debt	$792.10K	N/A
Cash on Hand	$1.70M	N/A
Debt to Equity	0.3091	62.84%
Cash to Debt	$2.15	-64.93%
Current Ratio	0.9057	-67.97%